Anti Virus Trial -

Before any human received AVI-7, Elena’s team tested it on human lung cell cultures infected with Phoenix. The drug reduced viral load by 99.9 percent within 48 hours without harming the cells. Next, they used ferrets—the gold standard for flu research—because ferrets cough, sneeze, and develop fever similarly to humans. Treated ferrets recovered fully; untreated ones died or suffered severe pneumonia.

The European Medicines Agency approved AVI-7 in December 2023 for adults with confirmed influenza A, conditional on kidney monitoring. Within nine months, Phoenix cases had declined by 60 percent in countries where the drug was deployed. anti virus trial

But the trial also revealed a serious flaw. In two patients with pre-existing kidney disease, the drug accumulated to toxic levels, causing acute renal failure. Both recovered after dialysis, but the data were clear: AVI-7 could not be given without prior kidney function screening. The drug’s label would need a bolded warning. Before any human received AVI-7, Elena’s team tested

Elena’s team had spent three years developing a broad-spectrum antiviral compound, code-named AVI-7. It worked differently from existing drugs: rather than targeting viral surface proteins (which mutate rapidly), AVI-7 attached to a host cell protein that the virus needed to replicate. In theory, this made it “resistance-proof.” But theory was not evidence. Treated ferrets recovered fully; untreated ones died or

Now came the hard part. Elena recruited 200 volunteers in a region with active Phoenix transmission. Half got AVI-7, half got placebo, double-blinded (neither patient nor doctor knew who got what). After 14 days, 18 people on placebo had confirmed Phoenix infections. In the AVI-7 group: just 3 infections, all mild. The drug showed 83 percent protection. But the real test was yet to come.

Dr. Márquez often told her students: “A trial isn’t a success because the drug works. It’s a success because we honestly learn what it can and cannot do—and we tell the truth about both.”